UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 9, 2006
Gen-Probe Incorporated
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
Delaware
(State or Other Jurisdiction
of Incorporation)
|
|
001-31279
(Commission File Number)
|
|
33-0044608
(I.R.S. Employer
Identification No.) |
10210 Genetic Center Drive
San Diego, CA 92121
(Address of Principal Executive Offices)
(858) 410-8000
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c))
TABLE OF CONTENTS
Section 5 — Corporate Governance and Management
Item 5.02(b). Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
(b) On February 9, 2006, Gerald D. Laubach, Ph.D., a director of Gen-Probe Incorporated (the
“Company”), informed the Company that he would retire as of the 2006 Annual Meeting of
Stockholders, scheduled to be held on May 17, 2006, and that he would not stand for reelection at
that meeting.
Dr. Laubach was President of Pfizer, Inc. from 1972 to 1990. He was initially elected as a
director of the Company on September 9, 2002, at the time of the Company’s spin-off from its former
parent, Chugai Pharmaceutical Co., Ltd.